Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck. He highlights progress in developing treatments for autoimmune diseases and anticipates milestones for the year ahead.
Copyright 2024 – Finance News Network
Source: Finance News Network
07 Oct 2022 - Stealth Global Holdings Limited (ASX:SGI) Group Managing Director Michael Arnold discusses the business offering, M&A activity, clients, 2025 strategy and financial targets.
Read More27 Sep 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes discusses the appointment of a US distributor for the company's APAS Independence instrument.
Read More16 Jun 2022 - Knosys Limited (ASX:KNO) Managing Director John Thompson provides an update on the company, discussing demand drivers, recurring revenue and growth strategy.
Read More11 Aug 2025 - Inside Etherstack’s multi-year partnership with the world’s largest telecom
Read More12 May 2021 - Galan Lithium (ASX:GLN) Managing Director Juan Pablo Vargas de la Vega provides an update on they company's key Hombre Muerto lithium brine project in the Catamarca province of Argentina.
Read More22 Nov 2021 - Arovella Therapeutics Limited (ASX:ALA) CEO & Managing Director Dr Michael Baker provides an update on the company's invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and conditions that affect the central nervous system.
Read More17 May 2022 - PropTech Group Limited (ASX:PTG) Managing Director and Group CEO Joe Hanna discusses drivers behind PropTech's results, providing an update on the company's growth strategies.
Read More08 Jun 2021 - Danakali Limited (ASX:DKM) Executive Chairman Seamus Cornelius discusses the company's Colluli project, including financing and economics, and the positive impact of the project on the region.
Read More21 Oct 2019 - PPK Group Limited (ASX:PPK) Executive Chairman, Robin Levinson talks about FY19 results, strategy, pickup in the company's key market, and the company's joint venture with Deakin University for Boron Nitrate Nanotubes.
Read More23 Sep 2024 - Rob Hattersley, Group Head of Capital at MaxCap Group, provides an overview of the company, discussing the funding gap in the Australian credit market, managing risk, the tailwinds for commercial real estate debt, and opportunities within the residential and logistics property markets.
Read More
